Heron Connect® | FAQs for APONVIE™ (aprepitant) injectable emulsion. See full Prescribing Information, including Boxed Warning for APONVIE, on this website.

Heron Connect^®

What is Heron Connect?

Heron Connect is a suite of programs and services that provide access and reimbursement support related to the use of APONVIE™. Our access solutions are designed to assist with questions related to billing and coding, payer coverage, benefit verification, drug returns, and more. Heron Connect is staffed by a dedicated team of Reimbursement Counselors who can answer questions and provide support tools.*

What type of prescriber can sign up patients for Heron Connect?

Any licensed prescriber can sign up patients for Heron Connect programs. Authorized prescribers may vary by state. In addition to medical doctors, prescribers may include physician assistants and nurse practitioners.

Is there a patient support line for patients?

Patients can call Heron Connect patient services at 1-844-HERON11 (1-844-437-6611) from 8:30 am to 5 pm ET, Monday through Friday.

What specific reimbursement and support services can Heron provide to our office?

Heron Therapeutics, Inc., provides offices with a variety of reimbursement and support services managed through a dedicated Reimbursement Counselor. Services include:

Patient-specific insurance verification, including eligibility and coverage information such as patient-specific benefits and anticipated out-of-pocket cost sharing responsibility for medical plan coverage based on the patient’s benefit design
Appeals support, including contacting the payer to understand the payer’s appeal process and providing appeal forms and guidance so that your office can complete the steps necessary to submit an appeal to the payer
Billing and coding support provided by dedicated Reimbursement Counselors to educate practices on billing, coding, and claims submission inquiries.

Does Heron offer any form of replacement policy?

Heron Therapeutics, Inc., offers a Drug Replacement Policy. In the event that the APONVIE 10-unit box is damaged during shipment or the product has expired, Heron Therapeutics, Inc., will provide a replacement. For more information, call Heron Connect at 1-844-HERON11 (1-844-437-6611) from 8:30 am to 5 pm ET, Monday through Friday.^†

Can Heron Connect help find other sources of financial support for patients, like support from foundations?

Heron Connect can research potential sources of financial support that might be available through independent charitable foundations.

IMPORTANT SAFETY INFORMATION

Contraindications

APONVIE is contraindicated in patients with a history of hypersensitivity to aprepitant or any component of the product, and in patients taking pimozide. Increased pimozide levels may cause serious or life-threatening reactions, such as QT prolongation.

Warnings and Precautions

Hypersensitivity Reactions: Serious hypersensitivity reactions, including anaphylaxis, during or soon after administration of aprepitant have occurred. Symptoms including dyspnea, eye swelling, flushing, pruritus, and wheezing have been reported. Monitor patients during and after administration. If hypersensitivity reactions occur, administer appropriate medical therapy. Do not administer APONVIE in patients who experienced these symptoms with previous use of aprepitant.

Clinically Significant CYP3A4 Drug Interactions: Aprepitant is a substrate, weak-to-moderate (dose-dependent) inhibitor, and an inducer of CYP3A4. Use of pimozide, a CYP3A4 substrate, with APONVIE is contraindicated. Use of APONVIE with strong CYP3A4 inhibitors (eg, ketoconazole) may increase plasma concentrations of aprepitant and result in an increased risk of adverse reactions related to APONVIE. Use of APONVIE with strong CYP3A4 inducers (eg, rifampin) may result in a reduction in aprepitant plasma concentrations and decreased efficacy of APONVIE.

Decrease in INR with Concomitant Warfarin: Use of aprepitant with warfarin, a CYP2C9 substrate, may result in a clinically significant decrease in the International Normalized Ratio (INR) of prothrombin time. Monitor the INR in patients on chronic warfarin therapy in the 2-week period particularly at 7 to 10 days, following administration of APONVIE.

Risk of Reduced Efficacy of Hormonal Contraceptives: The efficacy of hormonal contraceptives may be reduced for 28 days following administration of APONVIE. Advise patients to use effective alternative or back-up methods of non-hormonal contraception for 1 month following administration of APONVIE.

Use in Specific Populations

Avoid use of APONVIE in pregnant women as alcohol is an inactive ingredient in APONVIE. There is no safe level of alcohol exposure in pregnancy.

Adverse Reactions

Most common adverse reactions (incidence ≥3%) for APONVIE are constipation, fatigue, and headache and for oral aprepitant are constipation and hypotension.

Report side effects to Heron at 1-844-437-6611 or to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Frequently Asked Questions